

Ophthalmic Drugs: Data, Analysis and Forecasts to 2024

<https://marketpublishers.com/r/O0A71CC06C0EN.html>

Date: March 2014

Pages: 151

Price: US\$ 3,000.00 (Single User License)

ID: O0A71CC06C0EN

Abstracts

Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading GMR Data's new 'Ophthalmic Drugs; Data, Analysis and Forecasts to 2024' report, you can stay ahead of your competition. It really is that simple.

GMR Data forecasts that the global ophthalmic drugs market will reach \$9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example;

Xalabrand from Pfizer used for treatment of Glaucoma expired in the US in March 2011.

Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012.

Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.

Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014.

Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014.

Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022.

Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020.

Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of \$1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. With an assessment of the leading markets, such as the US, and EU, GMR Data examine how Germany and France are the largest EU markets and what % of the global market they make up. Which other countries contribute most? This report tells you in a concise, focused and easily accessible format.

But how will these country's markets develop? This report will tell you - TODAY

Global incidences of AMD, Glaucoma and Diabetic Retinopathy are all set to increase dramatically across the forecast period of 2014-2024; this will have the knock-on effect of driving sales of key drugs for treatment i.e. Lucentis and Eylea, as well as driving R&D. How much is being spent on R&D – and which drugs are likely to see a return? And how quickly?

Which new drugs will we see in the ophthalmic market across 2014-2024?

In December 2013 Santen announced that Ikervis (Ciclosporin / Cyclokate) was filed to the EMA, in doing so the EMA will begin its regulatory process. Diquas, which was launched in 2010 by Santen Pharma in Japan, China and other Asian markets, and despite US trials being unsuccessful, is expected to gain approval in the EU early in our forecast period.

Other key ophthalmic drugs currently under taking trials include;

Sirolimus (By Santen, in Phase III US)

Tafluprost/Timolol maleate (By Santen, filed for NDA)

Catioprost (By Santen in Phase 2)

PLUS – In-depth country analysis – Discover which countries and regions will drive the

ophthalmic drugs market to 2024?

Exclusive Industry sourced information, not available anywhere else

As well as primary and secondary research sources, GMR Data have interviewed leading ophthalmic specialists within big pharma, R&D, wholesalers, distributors, marketeers and key clinical organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field – This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Ophthalmic Drugs. This report will arm you with all you and your company require to develop, price, launch and market an ophthalmic drug.

With over 150 pages, and over 140 charts, tables and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Contents

1. EXECUTIVE SUMMARY

- 1.1 Ophthalmic Drugs Market Review
- 1.2 Chapter Breakdown
- 1.3 Research and Analysis Methods

2. CAUSES AND TREATMENTS OF OPHTHALMIC DISORDERS

- 2.1 Human Eye
- 2.2 Structure of Human Eye
- 2.3 Major Global Causes of Blindness & Vision Impairment
 - 2.3.1 Primary Causes of Blindness
 - 2.3.2 Primary Causes of Visual Impairment
 - 2.3.3 Geographic Breakdown of Global Blindness and Vision Impairment
 - 2.3.4 Primary Factors Contributing to Visual Impairment
- 2.4 The Most Common Type of Eye Disorders
 - 2.4.1 Cataracts
 - 2.4.2 Glaucoma
 - 2.4.3 Retinal Detachment
 - 2.4.4 Ophthalmic Allergies
 - 2.4.5 Ophthalmic Inflammatory Disorders
 - 2.4.6 Ophthalmic Infections
 - 2.4.7 Diabetic Retinopathy/Diabetic Mellitus
 - 2.4.8 Dry Eye
 - 2.4.9 Age-related Macular Degeneration

3. OPHTHALMOLOGY PHARMACEUTICAL MARKET & FORECAST

- 3.1 Major Trends and Issues
- 3.2 Global Ophthalmology Pharmaceuticals Market 2014-2024

4. ANTI-GLAUCOMA MARKET 2014-2024

- 4.1 Types of Glaucoma Eye Drops
- 4.2 Major Trends and Issues
- 4.3 Market Size and Forecast
- 4.4 Major Drugs & Forecast

- 4.4.1 Xalatan/Xalacom
- 4.4.2 Lumigan
- 4.4.3 Cosopt/Trusopt
- 4.4.4 Alphagan P, Alphagan and Combigan
- 4.4.5 Travatan
- 4.4.6 Azopt

5. OPHTHALMIC ANTI-ALLERGY/INFLAMMATION/INFECTIVE MARKET 2014-2024

- 5.1 Major Trends and Issues
- 5.2 Market Size and Forecast
- 5.3 Major Drugs and Forecast
 - 5.3.1 Patanol
 - 5.3.2 Vigamox/Vegamox
 - 5.3.3 Tobradex
 - 5.3.4 Pataday
 - 5.3.5 Cravit
 - 5.3.6 Xibrom/Bromday/Bromfenac

6. RETINAL DISORDERS MARKET 2014-2024

- 6.1 Major Trends and Issues
- 6.2 Market Size and Forecast
- 6.3 Major Drugs and Forecast
 - 6.3.1 Lucentis
 - 6.3.2 Eylea

7. DRY EYE MARKET 2014-2024

- 7.1 Major Trends and Issues
- 7.2 Market Size and Forecast
- 7.3 Major Drugs and Forecast
 - 7.3.1 Restasis
 - 7.3.2 Hyalein

8. REGIONAL LANDSCAPE

- 8.1 The US Ophthalmic Pharmaceutical Drugs Market 2013-2024
- 8.2 The UK Ophthalmic Pharmaceutical Drugs Market 2013-2024

- 8.3 The French Ophthalmic Pharmaceutical Drugs Market 2013-2024
- 8.4 The German Ophthalmic Pharmaceutical Drugs Market 2013-2024
- 8.5 The Spanish Ophthalmic Pharmaceutical Drugs Market 2013-2024
- 8.6 The Italian Ophthalmic Pharmaceutical Drugs Market 2013-2024
- 8.7 The Japanese Ophthalmic Pharmaceutical Drugs Market 2013-2024
- 8.8 The ROW Ophthalmic Pharmaceutical Drugs Market 2013-2024

9. OPHTHALMOLOGY R & D PIPELINE

- 9.1 Ophthalmology Drug R&D Pipeline for Glaucoma
- 9.2 Ophthalmology Drug R&D Pipeline for Anti-Infectives
- 9.3 Ophthalmology Drug R&D Pipeline for Anti-Inflammatory Agents
- 9.4 Ophthalmology Drug R&D Pipeline for Dry Eye
- 9.5 Gene Therapy in Ophthalmology – Ongoing Clinical Trial Details

10. LEADING COMPANIES

- 10.1 Alcon
- 10.2 Allergan
- 10.3 Argentis Pharmaceuticals LLC
- 10.4 Bausch & Lomb
- 10.5 Bayer Healthcare Pharmaceuticals
- 10.6 Eagle Vision Inc.
- 10.7 Eyegate Pharmaceuticals
- 10.8 Merck & Co
- 10.9 Novagali Pharma
- 10.10 Oasis Medical Inc.
- 10.11 Pfizer
- 10.12 Regeneron Pharmaceuticals Inc.
- 10.13 Resolvyx Pharmaceuticals Inc.
- 10.14 Roche
- 10.15 Santen Pharmaceutical Co Ltd

11. EXPERT OPINION

- 11.1 Dr David Sullivan, Associate Professor at Harvard Medical School
- 11.2 Dr Sonja Prager, Head of Diabetic Retinopathy Research Group, Vienna

I would like to order

Product name: Ophthalmic Drugs: Data, Analysis and Forecasts to 2024

Product link: <https://marketpublishers.com/r/O0A71CC06C0EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O0A71CC06C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970